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Crosstalk and complexity within signaling pathways
and their perturbation by oncogenes limit compo-
nent-by-component approaches to understanding
human disease. Network analysis of how normal
and oncogenic signaling can be rewired by drugs
may provide opportunities to target tumors with
high specificity and efficacy. Using targeted inhibi-
tion of oncogenic signaling pathways, combined
with DNA-damaging chemotherapy, we report that
time-staggered EGFR inhibition, but not simulta-
neous coadministration, dramatically sensitizes
a subset of triple-negative breast cancer cells to gen-
otoxic drugs. Systems-level analysis—using high-
density time-dependent measurements of signaling
networks, gene expression profiles, and cell pheno-
typic responses in combination with mathematical
modeling—revealed an approach for altering the
intrinsic state of the cell through dynamic rewiring
of oncogenic signaling pathways. This process
converts these cells to a less tumorigenic state that
is more susceptible to DNA damage-induced cell
death by reactivation of an extrinsic apoptotic
pathway whose function is suppressed in the onco-
gene-addicted state.INTRODUCTION
Standard therapies for the treatment of human malignancies
typically involve the use of chemotherapy or radiation therapy,
which function by damaging DNA in both normal and cancerous
cells (Lichter and Lawrence, 1995). Our growing understanding
of this process suggests that the DNA damage response (DDR)
functions as part of a complex network controlling many cellular
functions, including cell cycle, DNA repair, and various forms of780 Cell 149, 780–794, May 11, 2012 ª2012 Elsevier Inc.cell death (Harper and Elledge, 2007). The DDR is highly inter-
connected with other progrowth and prodeath signaling
networks, which function together to control cell fate in
a nonlinear fashion due to multiple levels of feedback and cross-
talk. Thus, it is difficult to predict a priori how multiple, often
conflicting signals will be processed by the cell, particularly by
malignant cells in which regulatory networks often exist in atyp-
ical forms. Predicting the efficacy of treatment and the optimal
design of combination therapy will require a detailed under-
standing of how the DDR and other molecular signals are inte-
grated and processed, how processing is altered by genetic
perturbations commonly found in tumors, and how networks
can be ‘‘rewired’’ using drugs individually and in combination
(Sachs et al., 2005).
In many forms of breast cancer, aberrant hormonal and/or
growth factor signaling play key roles in both tumor induction
and resistance to treatment (Hanahan and Weinberg, 2000).
Moreover, the identification of molecular drivers in specific
breast cancer subtypes has led to the development of more effi-
cacious forms of targeted therapy (Schechter et al., 1984;
Slamon et al., 1987). In spite of these advances, there are
currently no targeted therapies and no established molecular
etiologies for triple-negative breast cancers (TNBC), which are
a heterogeneous mix of breast cancers defined only by the
absence of estrogen receptor (ER) or progesterone receptor
(PR) expression and lack of amplification of the HER2 oncogene
(Perou et al., 2000). Patients with TNBCs have shorter relapse-
free survival and a worse overall prognosis than other breast
cancer patients; however, they tend to respond, at least initially,
to genotoxic chemotherapy (Dent et al., 2007). Triple-negative
patients generally do well if pathologic complete response is
achieved following chemotherapy.When residual disease exists,
however, the prognosis is typically worse than for other breast
cancer subtypes (Abeloff et al., 2008). Thus, identifying new
strategies to enhance the initial chemosensitivity of TNBC cells
may have substantial therapeutic benefit. Wewondered whether
a systems biology approach, focused on examining and manip-
ulating the interface between growth factor signaling pathways
and DNA damage signaling pathways in tumor cells, could
modulate the therapeutic response of this recalcitrant tumor
type. We report here that pretreatment, but not cotreatment or
posttreatment, of a subset of TNBCs with Epidermal Growth
Factor Receptor (EGFR) inhibitors can markedly synergize their
apoptotic response to DNA-damaging chemotherapy through
dynamic rewiring of oncogenic signaling networks and unmask-
ing of suppressed proapoptotic pathways. These results may
have broader implications for the testing, design, and utilization
of combination therapies in the treatment of malignant disease.
RESULTS
A Critical Order and Time Dependency for Enhanced
EGFR Inhibition/DNA Damage-Mediated Cell Death
Signaling networks can respond to, and can be functionally
rewired by, exposure to specific ligands or drugs (Janes et al.,
2005, 2008). It is increasingly clear that these responses are
time dependent. We reasoned that it should, in principle, be
possible to dynamically rewire the DDR network in an insensitive
cell through prior exposure to a drug that modulates the network,
thereby rendering the cell sensitive to DNA-damaging agents. To
test this hypothesis, we systematically investigated a series of
drug combinations for synergism or antagonism in breast cancer
cells using protocols that changed both the order and timing of
drug addition.
We combined genotoxic agents with small molecule inhibitors
targeting common oncogenic signaling pathways (Figure 1A).
We included drugs that are known to be clinically useful in other
cancers but are known to lack efficacy in TNBC individually or in
combination (Bosch et al., 2010; Winer and Mayer, 2007).
Previous studies using cell culture models of TNBC, for example,
reported that EGFR inhibitors in combination with genotoxic
compounds such as cisplatin resulted in less than a 10% survival
benefit (Corkery et al., 2009), whereas a randomized phase II trial
in TNBC patients reported that addition of cetuximab to carbo-
platin did not improve outcome (Carey et al., 2008). However,
emerging understanding of the complex nonlinear and time-
dependent interplay between signaling networks argues that
a more systematic assessment exploring not only dosage, but
also the order of drug presentation, scheduling, and dose dura-
tion might uncover cross-pathway effects and efficacious inter-
actions that were missed previously (Fitzgerald et al., 2006). An
initial combination screen was therefore performed in a panel
of canonical breast cancer cell lines representing those
that are hormone sensitive (MCF7), HER2 overexpressing
(MDA-MB-453), or triple negative (BT-20) (Neve et al., 2006). A
first pass of the screen, scoring for viability, was performed in
BT-20 cells, and a subset of combinations was then explored
more thoroughly, scoring for viability, proliferation, and apoptotic
responses in the panel of three cell lines (Figures 1B–1E and Fig-
ure S1 available online).
Consistent with previous reports, we found that inhibition of
EGFR using the compound erlotinib (ERL) was not a potent
apoptotic stimulus in TNBC cells when used alone or when
added at the same time as or shortly before doxorubicin (DOX)
(Figure 1B, left bars 1–6). Surprisingly, however, combinations
in which erlotinib was added at least 4 hr prior to doxorubicin
showed a markedly enhanced apoptotic response, with cellkilling increasing by as much as 500% (Figure 1B, middle bars
7–10). When the order of drug presentation was reversed—
doxorubicin given before erlotinib—cell killing was not enhanced
relative to treatment with doxorubicin or erlotinib alone
(Figure 1B, right bars 11 and 12). The efficacy of the time-
sequenced erlotinib-doxorubicin treatment was analyzed for
doxorubicin dose-effect relationships using the Chou-Talalay
method (Chou and Talalay, 1984) and was found to vary sig-
nificantly across breast cancer subtypes (Figures 1C–1E
and 1G). Whereas chronic EGFR inhibition was synergistic
with doxorubicin in killing TNBC BT-20 cells, the same treat-
ment regimen antagonized doxorubicin sensitivity in HER2-
overexpressing MDA-MB-453 cells. All temporal erlotinib-
doxorubicin combinations tested were merely additive in luminal
MCF7 cells. The order and timing of drug addition had little effect
in Hs578Bst, a cell line derived from normal peripheral breast
tissue, which was generally drug resistant (Figure 1F).
Furthermore, this enhanced treatment effect in BT-20 cells
was not limited to combinations of doxorubicin and erlotinib.
Synergistic killing was also observed following time-staggered
pretreatment of BT-20 cells with either erlotinib, gefitinib, or lapa-
tinib (all EGFR inhibitors) in combination with the DNA-damaging
agent camptothecin, as well as with doxorubicin (Figures S1A–
S1C) (Wood et al., 2004).
Sustained EGFR Inhibition Suppresses Oncogenic
Signatures and Rewires the Intrinsic State of the Tumor
Cells to a More Chemosensitive Form
Although erlotinib inhibits EGFR and downstream signaling
within minutes (Figures S2A and S2B), enhanced cell death in
response to DNA-damaging agents required pretreatment with
erlotinib for several hours. To verify that this was indeed due to
on-target inhibition of EGFR, in addition to testing other EGFR
inhibitors (above), we knocked down EGFR using two different
small interfering RNAs (siRNAs). Like the time-staggered erloti-
nib-doxorubicin treatment, strong proapoptotic responses
were observed in BT-20 cells following EGFR knockdown with
delayed doxorubicin treatment (Figures 1H and 1I). Importantly,
the addition of erlotinib to EGFR knockdown cells had no addi-
tional effect, arguing against an off-target effect of the drug. As
a further test, we also examined coadministration of higher
concentrations of erlotinib instead of time-staggered doses
without observing increased apoptosis (Figure S2C). Taken
together, these data indicate that enhanced cell death observed
using time-staggered erlotinib-doxorubicin combinations is
directly mediated by sustained EGFR inhibition.
Potential explanations for the increased sensitivity of cells to
doxorubicin following sustained EGFR inhibition includemodula-
tion of cell-cycle progression, altered rates of doxorubicin influx/
efflux, or changes in levels of DNA damage itself. To examine
these, we monitored cell-cycle progression at five time points
over 24 hr in our panel of breast cancer cell lines. Although doxo-
rubicin and erlotinib altered cell-cycle dynamics depending on
the cell type, cells that received both drugs had similar cell-cycle
profiles regardless of the dosing regimen (Figures 2A–2D and
S2D). In particular, there is no evidence that cells exposed to
the ERL/DOX protocol accumulate in S/G2, the cell-cycle
stage during which doxorubicin may be most effective. Thus,Cell 149, 780–794, May 11, 2012 ª2012 Elsevier Inc. 781
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Figure 1. A Screen for Novel Combination Treatment Reveals Dosing Schedule-Dependent Efficacy for Killing TNBC Cells
(A) Schematic of combinations tested. Seven genotoxic drugs and eight targeted signaling inhibitors were tested in pair-wise combinations, varying dose, order of
presentation, dose duration, and dosing schedule.
(B) Apoptosis in BT-20 cells. Cleaved-caspase 3/cleaved-PARP double-positive cells were quantified using flow cytometry (bottom). In cells treated with DMSO,
erlotinib (ERL), or doxorubicin (DOX), apoptosis measurements were performed 8 hr after drug exposure or at the indicated times. D/E, ERL/DOX, and DOX/
ERL refer to DOX and ERL added at the same time, ERL given at the indicated times before DOX, and DOX given at the indicated times before ERL, respectively.
For each, apoptotic measurements were made 8 hr after the addition of DOX. Erlotinib and doxorubicin were used at 10 mM. Mean values ±SD of three inde-
pendent experiments, each performed in duplicate, are shown (top).
(C–F) Apoptosis in different subtypes of breast cancer. Apoptosis was measured as in (B). (D and E) E/D and D/E refer to DOX and ERL added at the same
time, ERL given 24 hr before DOX, and DOX given 4 hr before ERL, respectively. Data are mean values ±SD of three independent experiments.
(G) Dose-response profiles of erlotinib/doxorubicin drug combinations. Apoptosis was measured as in (B). Drugs were added at a 1:1 ratio, and combination
index (CI) was calculated according to the Chou-Talalay method.
(H) Knockdown of EGFR in BT-20 cells measured 48 hr after addition of the indicated siRNA by immunoblotting (left). EGFR expression relative to ‘‘no RNA’’
control is quantified on right.
(I) Apoptosis in BT-20 cells ± EGFR knockdown measured as in (B). Scrambled RNAi shown as control. Data shown are the mean ±SD of both siRNAs, each
performed in biological duplicate.
See also Figure S1.
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Figure 2. Prolonged Treatment with Erlotinib Does Not Change Cell-Cycle Profile, Doxorubicin Influx/Efflux, or the Level of DNA Damage
(A–D) Quantitative cell-cycle analysis. DNA content and the percentage of mitotic cells were measured by FACS. (A) Example FACS plots from untreated BT-20
cells. (B–D) Cell-cycle stage quantified from three experiments, each performed in duplicate. Cells were treated as in Figure 1, and data were collected at 6, 8, 12,
24, and 48 hr after DOX treatment. 8 hr data shown for each cell type.
(E–H) Doxorubicin retention measured by flow cytometry. (E) Sample time course of BT-20 cells treated with 10 mM DOX for the indicated times. (F–H) Cells
treatedwith doxorubicin or pretreatedwith erlotinib for 24 hr prior to DOX (E/D). Cells were collected at 1, 4, or 8 hr after DOX exposure as indicated, and internal
doxorubicin fluorescence was measured.
(I and J) Quantitative microscopy of the early DNA double-stranded break response. (I) Example image of cells treated with DOX for 1 hr and stained for gH2AX,
53BP1, or nuclear content (DAPI). (J) Integrated intensity per nucleus of gH2AX and 53BP1 foci was measured in BT-20 cells after the indicated treatments and
times. Mean values ± SD from triplicate experiments shown.
(K) Western blot analysis of gH2AX in BT-20 cells. b-actin shown as a loading control.
See also Figure S2.cell-cycle modulation cannot explain the unique efficacy of
sequential drug exposure. Some membrane pumps can be
modulated by EGFR inhibitors (Lopez et al., 2007; Turner et al.,
2006) and are responsible for multidrug resistance in at least
some breast cancers (Woehlecke et al., 2003). We therefore
measured the intracellular accumulation of doxorubicin by flow
cytometry and found that prior treatment with erlotinib did not
alter the intracellular doxorubicin concentration (Figures 2E–
2H). Next, as pharmacodynamic markers of doxorubicin action,
we assayed two indicators of DNA double-stranded breaks:
phosphorylation of histone H2AX at S139 and formation of
53BP1-containing nuclear foci. Both assays showed similar
responses across all treatment conditions (Figures 2I–2K). Taken
together, these data indicate similar levels of DNA damage and
early DNA damage-related signaling in DOX- and ERL/DOX-
treated cells independent of the efficacy of the combination in
cell killing.
The absence of demonstrable changes in cell-cycle states,
intracellular doxorubicin concentrations, or doxorubicin-inducedDNA damage suggested that prolonged EGFR inhibition neces-
sary for effective tumor cell killing might result from rewiring of
the signaling networks that control responses to genotoxic
stress. To investigate this idea, we measured changes in gene
expression in cells treated with erlotinib alone. In triple-negative
BT-20 cells, EGFR inhibition for 30 min resulted in few differen-
tially expressed genes (DEGs) (Figure S3A). Following 6 hr of
erlotinib treatment, however, we observed >1,200 DEGs, and
following 24 hr of treatment, when doxorubicin sensitivity was
maximally enhanced, we observed >2,000 DEGs (Figures 3A
and S3B). By comparison, in the HER2+ MDA-MB-453 cells,
which were desensitized to doxorubicin by erlotinib exposure,
we observed only 235DEGs following 24 hr exposure to erlotinib,
and in hormone-sensitive MCF7 cells, only one gene was
significantly altered (Figures 3B and 3C). Thus, the triple-
negative BT-20 cells exhibited progressive and large-scale
changes in gene expression following EGFR inhibition that
were not observed in cell lines insensitive to the time-staggered
ERL/DOX combination.Cell 149, 780–794, May 11, 2012 ª2012 Elsevier Inc. 783
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Figure 3. Triple-Negative BT-20 Cells Are Driven by Oncogenic EGFR Signaling
(A–C) DEGs following erlotinib treatment for 24 hr versus untreated cells. Cut-off for DEGwasR 2-fold change and a p value% 0.05 (genes that meet both criteria
are colored red). B score is the log of the odds of differential expression.
(D) DEGs classified using GeneGO ‘‘pathway maps.’’ Heatmap (left) colored according to –log (p value); (right) p value cut-off was 0.05 (dotted red line).
(E and F) Microarray analysis using GSEA reveals loss of oncogene signatures in BT-20 cells after sustained EGFR inhibition. Ras oncogenic signature and false
discovery rate (FDR)-adjusted p values are shown in (E). Eleven oncogenic signatures from the Molecular Signatures Database (MSigDB) are shown in (F). Boxes
are colored according to normalized enrichment score (NES).
784 Cell 149, 780–794, May 11, 2012 ª2012 Elsevier Inc.
To examine which cellular processes were altered by long-
term erlotinib treatment, DEGs in BT-20 cells were categorized
by cellular process according to the GeneGO pathway annota-
tion software (Ekins et al., 2007). Significant changes were
observed in 16 of 34 GeneGO cellular networks, including those
that mediate the DDR, apoptosis, and inflammation (Figure 3D).
In contrast, DEGs in MDA-MB-453 were not only fewer in
number, but also lay in networks that did not overlap with those
altered in BT-20 cells (Figure 3D). We further analyzed gene
expression data using gene set enrichment analysis (GSEA),
a tool for identification of enrichment or depletion of defined
gene expression signatures within a rank-ordered gene list
(Subramanian et al., 2005). The most statistically significant
changes in BT-20 cells upon sustained erlotinib exposure were
loss of the Ras and MYC oncogenic signatures (Figure 3E).
These signatures were not significantly altered in MDA-MB-453
or MCF7 cells treated with erlotinib for 24 hr or in BT-20 cells
exposed to erlotinib for 30 min (Figure 3E). Within the GSEA
molecular signatures database, there exist 11 oncogenic signa-
tures (Subramanian et al., 2005). GSEA of EGFR-inhibited BT-20
cells showed a similar depletion pattern for all 11 oncogenic
signatures (Figure 3F). These changes were not consistently
observed in either MDA-MB-453 cells or MCF7 cells following
exposure to erlotinib.
Distinct gene expression patterns have been used to define
breast cancer subtypes. BT-20 cells, like most triple-negative
cells, display a ‘‘basal-like’’ gene expression signature (Neve
et al., 2006). Strikingly, analysis of our expression data set
revealed that chronic erlotinib treatment of BT-20 cells caused
progressive time-dependent loss of basal-like gene expression
with concomitant gain in luminal A-like gene expression, a breast
cancer subtype with the least aggressiveness and best overall
prognosis (Figure 3G). In contrast, no such switch in breast
cancer subtype patterns of gene expression was observed in
HER2-overexpressing MDA-MB-453 cells or hormone-sensitive
MCF7 cells following erlotinib exposure.
These expression data suggest that the oncogenic potential of
BT-20 cells is maintained by chronic EGFR-driven patterns of
gene expression and that this cell state could be remodeled
through sustained inhibition of EGFR. To directly test this, we
examined the ability of BT-20 cells to form colonies in soft
agar, a classic test of transformation that typically shows good
correlation with tumorigenic potential in vivo (Montesano et al.,
1977). Consistent with the predictions derived from our GSEA,
sustained EGFR inhibition with erlotinib potently inhibited soft
agar colony formation (Figure 3H).
Creation of a Data-Driven Model for Combined EGFR
Inhibition/DNA Damage
To better understand the biochemical changes in signaling that
accompany time-staggered ERL/DOX treatment, we used
quantitative high-throughput reverse-phase protein microarrays(G) GSEA reveals a switch from basal to luminal A genetic signature in BT-20 cells
cancer subtype-specific genetic signatures as defined by Sørlie et al. (2001).
(H) BT-20 cells lose the ability to form colonies in soft agar upon EGFR inhibition.
colony formation 21 days later.
See also Figure S3.and quantitative western blotting to measure the levels or acti-
vation states of 35 signaling proteins within multiple signaling
pathways at 12 time points following exposure to erlotinib
and doxorubicin both individually and in combination (Figures
4A–4D and see Figure S4 for a description of the selection of
35 proteins for analysis) (MacBeath, 2002). Oncogenic signaling
networks typically exhibit multiple levels of feedback and
crosstalk with other networks, rendering single protein
measurements ineffective in predicting complex cellular
responses to drugs such as those leading to DNA damage-
induced apoptosis (Fitzgerald et al., 2006). We therefore con-
structed a multifactorial data-driven mathematical model
relating signaling ‘‘inputs’’ to phenotypic ‘‘outputs.’’ In addition
to examining signaling pathways known to contribute to the
DDR, we used our list of differentially expressed genes (Fig-
ure 3) to identify other proteins that might function as critical
signaling nodes. This DEG-expanded list of signaling proteins
extends far beyond the canonical components of the DDR,
including proteins involved in apoptotic and nonapoptotic
death, growth and stress responses, and cytokine/inflamma-
tory signaling (Figure S4A). Specific proteins, whose measure-
ment was motivated by gene expression data, included Bcl2-
interacting mediator of cell death (BIM), BH3-interacting
domain (BID), capase-8, 4E-BP1, S6K, Stat3, DUSP6, and
inhibitor of kappa B (IKB). Phenotypic responses, including
cell-cycle arrest and progression, autophagy, and apoptotic
and nonapoptotic cell death, were scored at six time points
using luminescent microplate assays, flow cytometry, and
automated microscopy (Figures 4E and S4C–S4F). All signaling
and phenotypic response measurements were performed in
biological and experimental triplicate in BT-20, MDA-MB-453,
and MCF7 cells. In total, this data set comprised more than
45,000 measurements of molecular signals and 2,000 measure-
ments of cellular responses (Figures 4A and 4E), revealing
many changes in cell state and phenotype associated with
drug exposure.
Several mathematical modeling approaches were employed
to relate signaling data to cell phenotypes. Initial modeling efforts
used principal component analysis (PCA) to identify covariation
between signals, whereas partial least-squares (PLS) regression
was used to identify statistically significant covariation between
molecular signals and corresponding cellular responses (Fig-
ure S4B) (Janes and Yaffe, 2006). In both PCA and PLS
modeling, vectors were constructed whose elements contained
quantitative measures of the level, state, and/or activity of
specific signaling proteins. The vectors were then reduced to
a set of principal components, calculated so that each additional
PCA or PLS dimension maximally captures information not
captured by preceding components. This processwas iteratively
repeated until additional principal components ceased to
capture meaningful data, as judged relative to experimental
noise.following sustained EGFR inhibition. Expression analyzed as in (F) using breast
Cells were untreated or treated with ERL, grown in soft agar, and monitored for
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Figure 4. A Systems-Level Signal-Response Data Set Collected Using a Variety of High-Throughput Techniques
(A–D) (A) The complete signaling data set for three different breast cancer subtypes following combined EGFR inhibition and genotoxic chemotherapy treatments
as in Figure 1. Each box represents an 8 or 12 point time course of biological triplicate experiments. Time course plots are colored by response profile, with early
sustained increases in signal colored green, late sustained increases colored red, and transient increases colored yellow. Decreases in signal are colored blue.
Signals that are not significantly changed by treatment are shaded gray to black with darkness reflecting signal strength. Numbers to the right of each plot report
fold change across all conditions and/or cells. (B) Sample detailed signaling time course from (A), highlighted by dashed box and asterisk, showing p-ERK
activation in BT-20 cells. Mean values ±SD of three experiments are shown. (C) Forty-eight-sample western blots analyzed using two-color infrared detection.
Each gel contained an antibody-specific positive control (P) for blot-to-blot normalization. The example shown is one of three gels for total p53 in MCF7 cells (p53
in green; b-actin in red). (D) Reverse-phase protein lysate microarrays were used to analyze targets of interest when array-compatible antibodies were available.
The slide shown contains 2,500 lysate spots (experimental and technical triplicates of all of our experimental samples, and control samples used for antibody
calibration), probed for phospho-S6.
(E) The complete cellular response data set, colored as in (A).
See also Figure S4 and Table S1.Following PCA, multiplex data from MDA-MB-453 cells pro-
jected negatively along principal component one (PC1), data
from BT-20 cells projected positively along PC1, and MCF7
data were largely neutral (Figures 5A and S5A). Thus, the first
principal component captured cell type-specific variance in the
data. In contrast, data from all cell types projected similarly along
PC2 but in a manner that was drug dependent. Data from
DMSO- or erlotinib-treated cells not exposed to doxorubicin
projected negatively along PC2, whereas data from cells786 Cell 149, 780–794, May 11, 2012 ª2012 Elsevier Inc.cotreated with doxorubicin and erlotinib or exposed sequentially
to ERL/DOX projected positively along PC2. Finally, data from
cells treated with doxorubicin alone or DOX/ERL were largely
neutral along PC2. Thus, the second principal component
captured signaling variance from treatment-specific modulation
of the signaling networks regardless of cell type (Figure 5A).
These data suggest that, although significant differences in the
state of the networks exist between cell lines, the drugs that
we applied modulated signaling networks in similar ways across
Figure 5. A PLS Model Accurately Predicts Phenotypic Responses from Time-Resolved Molecular Signals
(A) Principal components analysis of covariation between signals. Scores plot represents an aggregatemeasure of the signaling response for each cell type under
each treatment condition at a specified time, as indicated by the colors and symbols in the legend.
(B and C) Scores and loadings for a PLS model. (B) Scores calculated and plotted as in (A), except the principal components now reflect covariation between
signals and responses. (C) PLS loadings plotted for specific signals and responses projected into principal component space.
(D–I) BT-20 cell line-specific model calibration. (D) R2, Q2, and RMSE for BT-20 models built with increasing numbers of principal components. (E and F) Scores
and loadings plots, respectively, for a two-component model of BT-20 cells. (G–I) Apoptosis as measured by flow cytometry or as predicted by our model using
jack-knife cross-validation. R2 reports model fit, and Q2 reports model prediction accuracy. (G) Final refined model of apoptosis in BT-20. (H) BT-20 model minus
targets identified as DEGs in microarray analysis. (I) Model using only the top four signals: c-caspase-8, c-caspase-6, p-DAPK1, and pH2AX.
See also Figure S5.all lines examined. PLS analysis linking signals to responses
gave similar results, with differences between the cell lines
now captured in both PC1 and PC2 and treatment-specific vari-
ance emerging in the third principal component, PC3 (Figures 5B
and S5B–S5E). The expected differences that we observed
between these cell types, captured by both PCA and PLS anal-
yses, confirm that the signaling molecules we measured can be
used to define both the cell-type-specific and drug treatment-
specific differences between these cells.
Based on these cell-type-specific differences in the global
PCA/PLS model, we next built models for each cell line inisolation, focusing primarily on triple-negative BT-20 cells. To
optimize the BT-20 PLS model, we compared fitness measures
such as R2 (percent of variance captured by model), Q2 (percent
of variance predicted by the model using a leave-one-out cross-
validation approach), and root-mean-square error (rmse; the
mean deviation between model and data) across models
containing increasing numbers of principal components. With
BT-20 data alone, >97% of the variance linking signals to
responses under different conditions of drug treatment was
captured by two principal components. Incorporation of addi-
tional components actually reduced the predictive ability of theCell 149, 780–794, May 11, 2012 ª2012 Elsevier Inc. 787
model (Figure 5D), a common finding reflecting the addition of
noise when components with little predictive value are added.
Similar trends were observed for each of the other cell lines.
To derive molecular understanding from the models, we pro-
jected the loading vectors (i.e., individual signals and responses)
into PLS component space. We observed a strong anticorrela-
tion between the apoptotic and proliferative responses (Figures
5C and 5F) that was captured by the first principal component
in the BT-20 model (Figure 5F) and by the second principal
component in the aggregate cell line model (Figure 5C). To
further test model quality, we compared each measured cellular
response in isolation to that predicted by the model using jack-
knife-based cross-validation (Figures S5F–S5L). Our model
was particularly accurate at predicting apoptosis following
treatment (Figure 5G) and was moderately good at predicting
proliferation and autophagy (Figures S5K and S5L). Other
responses (G1, G2, and S) were not predicted as accurately,
likely due to the limited dynamic range in our cell-cycle response
data set (Figures S5G–S5J).
PLS Modeling Reveals that Chemosensitization
following Network Rewiring Is Driven by Caspase-8
Activation
Because PLS models of individual cell lines could accurately
predict apoptosis, we analyzed the models to identify specific
proteins or signals that might account for the enhanced sensi-
tivity of BT-20 cells to doxorubicin following EGFR inhibition.
The BT-20 two-component PLS model identified four signals
(cleaved caspase-8, cleaved-caspase-6, phospho-DAPK1, and
phospho-H2AX) that were highly covariant with apoptosis (Fig-
ure 5F). Remarkably, a model including only these four signals
was just as accurate at predicting apoptosis as the complete
35-signal model (Figures 5G–5I). Notably, of these signals, only
pDAPK1 would have been identified using the aggregate cell
line PLS model (Figure 5C). We reasoned that the enhanced
sensitivity of BT-20 cells to doxorubicin, mediated by erlotinib
pretreatment, likely involved one of these molecular signals.
We therefore calculated and plotted the ‘‘variable importance
in the projection’’ (VIP) score for each signal (Figure 6A). The
VIP score reports the sum (over all model dimensions) of each
variable x (molecular signals in this case), weighted by the
amount of the cellular response y (apoptosis) explained by vari-
able x. Strikingly, caspase-8, an initiator caspase in death
receptor-mediated apoptosis, was the single most important
variable for predicting apoptosis in BT-20 cells and was simulta-
neously among the least important variables in MDA-MB-453
and MCF7 cells. Caspase-8 has previously been implicated in
cell death mediated by EGFR inhibition in other contexts (Kang
et al., 2010; Morgillo et al., 2011); however, erlotinib alone did
not cause death in any of our cell types. Instead, apoptosis in
these cells and the potential importance of caspase-8 resulted
from their exposure to the genotoxic agent doxorubicin. In
most cells, DNA damage activates cell-intrinsic apoptosis medi-
ated through caspase-9 (c.f., Figure 5C), not caspase-8 (Kim,
2005). Thus, the strong influence of caspase-8 was unexpected.
As an in silico test for the importance of caspase-8 in particular
erlotinib/doxorubicin protocols, we set caspase-8 activity to
zero in the model and left all other variables unchanged. The788 Cell 149, 780–794, May 11, 2012 ª2012 Elsevier Inc.BT-20 model specifically predicted a dramatic decrease in the
enhanced sensitivity to doxorubicin following sustained erlotinib
treatment (Figure 6B), with much smaller decreases in apoptosis
occurring under all other treatments. In contrast, the apoptosis
model for MDA-MB-453 cells predicted no change following
loss of caspase-8 activity under any conditions (Figure 6C). To
test these predictions experimentally, two separate caspase-8
siRNAs were used in both BT-20 cells and MDA-MB-453 cells
(Figures 6D and 6E). In excellent agreement with the model,
knockdown of caspase-8 mitigated the enhanced cell death
following erlotinib treatment in BT-20 cells while having minimal
effect on apoptosis following other treatment combinations (Fig-
ure 6F). Furthermore, caspase-8 knockdown had little effect on
apoptosis in MDA-MB-453 under any condition (Figure 6G). To
further assess model predictions and evaluate the relative
importance of caspase-8 in the enhanced doxorubicin-induced
apoptosis, we tested several other model-generated predic-
tions, including proteins predicted to contribute strongly
(caspase-6), moderately (Beclin-1), or weakly (RIP1) to apoptosis
in BT-20 cells. Based on the VIP plot and loadings projections,
caspase-6 is predicted to be a strong driver of the apoptotic
response in BT-20 and MDA-MB-453 cells, but not MCF7 cells;
Beclin-1 is predicted to be moderately antiapoptotic in BT-20
cells but has no role in the other cell lines; and RIP1 is predicted
to be weakly antiapoptotic in BT-20 and MDA-MB-453 cells but
strongly antiapoptotic in MCF7 cells. As shown in Figure S6, we
were able to confirm these cell type dependences using siRNA
and confirm the relative magnitude of the effect of each target
on the apoptotic response following various combinations of
erlotinib and/or doxorubicin. Importantly, although caspase-6
contributed strongly to cell death in BT-20 cells, caspase-8
remained the strongest predictor. None of the other targets
tested modulated the apoptotic response to the same extent
as caspase-8, further highlighting its importance. Thus, the
increased cell killing by ERL/DOX treatment in BT-20 cells
appears to involve rewiring of the DNA damage response,
allowing activation of both cell-intrinsic and -extrinsic apoptotic
programs to contribute to cell death.
Time-Staggered Inhibition of EGFR Enhances Apoptotic
Response in a Subset of TNBC Cells and Other
Oncogene-Driven Cells
To examine whether the efficacy of time-staggered ERL/DOX
treatment was unique to BT-20 cells or potentially amore general
phenomenon of TNBC cells, we examined a handful of other
triple-negative cell lines (Neve et al., 2006). The selected cell
lines have markedly different growth rates, EGFR expression
levels, and p53 states (Figure S7A). Despite these differences,
sustained EGFR inhibition enhanced sensitivity to doxorubicin
in nine of ten triple-negative cell lines tested. A synergistic effect,
however, was observed in only four of the ten TNBC lines
(Figures 7A, S7A, and S7B). To identify potential reasons for
this, we measured total EGFR protein levels and basal EGFR
activation by immunoblotting. Our quantitative measurement of
EGFR protein expression was very similar to previously reported
values (Neve et al., 2006) and correlated only very weakly with
sensitivity to ERL/DOX treatment (Figures 7A and 7B). In
marked contrast, the levels of basal EGFR activity exhibited
AB D F
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Figure 6. Enhanced Sensitivity to Doxorubicin Is Mediated by Caspase-8 Activation
(A) VIP scores for predicting apoptosis plotted for each cell line-specific PLS model. VIP score >1 indicates important x variables that predict y responses,
whereas signals with VIP scores <0.5 indicate unimportant x variables.
(B and C) Model-generated predictions of apoptosis with (blue) or without (red) caspase-8 activation 8 hr after the indicated treatments in BT-20 (B) and 453 (C).
(D and E) Western blot verifying caspase-8 knockdown in BT-20 (D) and 453 (E).
(F and G) Measured apoptosis 8 hr after the indicated treatment in cells expressing control RNA or caspase-8 siRNA. (F) BT-20. (G) 453. In both (F) and (G),
apoptotic values represent mean response ±SD from both siRNAs, each in duplicate.
See also Figure S6.a much higher correlation (Figures 7A and 7B). Furthermore, in
those TNBC cell lines in which ERL/DOX treatment was syner-
gistic, we consistently observed caspase-8 cleavage following
sequential administration, but not other drug treatments, sug-
gesting a similar mechanism of enhanced apoptosis in these
cells as that observed in BT-20 cells (Figures 7A and 7B). Taken
in context with our observation that EGFR signaling drives
expression of an oncogenic gene expression signature in
BT-20 cells, these findings suggest that a subset of triple-
negative cell lines are similarly driven by aberrant EGFR
signaling. Importantly, however, these cells could not be distin-
guished by measuring EGFR gene amplification or EGFR
abundance. Instead, they are unique in displaying high levels
of activated (phosphorylated) EGFR as a biomarker of response
to time-staggered EGFR inhibition and cytotoxic treatment.
We next investigated whether the initial chemosensitizing
effects of an ERL/DOX protocol could be observed when
treating EGFR-driven triple-negative tumors in vivo. BT-20 cellswere injected into the flanks of nude mice, and tumors were
allowed to form for 7 days before treatment with either doxoru-
bicin alone or erlotinib-doxorubicin combinations. Following
a single dose of doxorubicin alone, a marked reduction in tumor
volume was observed over the first 3 days after treatment.
The residual tumors continued to grow, however, reaching
pretreatment volume after 14 days (Figure 7C). A similar trend
wasobserved for tumorscotreatedwitherlotinibanddoxorubicin,
although the initial reduction in tumor sizewasgreater. Incontrast,
when mice were given erlotinib 8 hr prior to doxorubicin, the
tumors not only exhibited a similar initial reduction in size, but
also failed to regrow throughout the 14 day monitoring period.
Thus, the chemosensitizing effect of sequential ERL/DOX treat-
ment seen in culture was also observed in vivo. These results
suggest that time-staggered inhibition of EGFR, in combination
with DNA damaging agents, could be a potentially useful thera-
peutic strategy for treating a subset of triple-negative tumors,
particularly those with high basal levels of phosphorylated EGFR.Cell 149, 780–794, May 11, 2012 ª2012 Elsevier Inc. 789
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We next examined whether the principle of time-staggered
inhibition would sensitize other breast cancer subtypes to doxo-
rubicin. In contrast to BT-20 cells, MDA-MB-453 cells were not
sensitized by sustained EGFR inhibition but instead were desen-
sitized to DNA-damaging chemotherapy (Figure 1D). However,
MDA-MB-453—and other widely used cell lines like BT-474—
have a well-established oncogene addiction to HER2 (Neve
et al., 2006). We therefore tested time-staggered inhibition of
HER2 using the drug lapatinib (a potent inhibitor of both EGFR
and HER2) in combination with doxorubicin in these cells. In
both MDA-MB-453 and BT-474 cells, in contrast to the desensi-
tization caused by pretreatment with erlotinib, we observed that
lapatinib pretreatment enhanced sensitivity to doxorubicin to
a similar extent as the enhancement observed with erlotinib in
BT-20 and other EGFR-driven TNBC cells (Figures 7C and
S7C). Importantly, whereas all temporal combinations of
lapatinib and doxorubicin were synergistic in HER2-overex-
pressing cells, pretreatment with lapatinib resulted in the largest
increase in apoptosis. Furthermore, caspase-8 cleavage was
only observed following LAP/DOX treatment of HER2-driven
cells, but not by other drug combinations. Knockdown of
caspase-8 in these cells eliminated the specific component of
enhanced cell death observed only in the pretreatment condition
(Figures 7C and S7C), suggesting that this portion of the overall
cell death was driven by caspase-8 activity.
Finally, we examined whether the efficacy of time-staggered
inhibition of EGFR was limited to breast cancer cells. Many
lung cancers, for example, contain either high levels of phos-
phorylated wild-type EGFR or mutations within EGFR itself.
We therefore tested our ERL/DOX treatment protocol on
NCI-H1650 cells, a lung cancer cell that contains an in-frame
deletion that is commonly seen in lung cancers (Sordella et al.,
2004), as well as on A549 and NCI-H358, cells that have high
levels of phosphorylated wild-type EGFR, possibly due to
HER2 amplification (Balko et al., 2006; Diaz et al., 2010; Helfrich
et al., 2006; Rusnak et al., 2007). Remarkably, in all three lung
cancer cell lines, we found that time-staggered inhibition of
EGFR using erlotinib caused a dramatic sensitization to killing
by doxorubicin that was associated with caspase-8 cleavage
(Figures 7E, 7F, and S7D). Furthermore, knockdown of
caspase-8 largely abrogated the enhanced cell death observedFigure 7. Time-Staggered Inhibition of EGFR Signaling Enhances Apo
Cells
(A) Panel of TNBC cell lines with a wide range of EGFR expression levels. Heatm
relative to DOX alone, and casp-8 cleavage. Apoptosis measured as in Figure 1.
cells. Cleaved casp-8 measured by western blot 8 hr after exposure to DOX.
(B) EGFR activity, but not total EGFR expression, is correlatedwith sensitivity to tim
in E/D relative to DOX alone regressed against total EGFR or p-EGFR (pY1173)
R2 reports the linear fit for each trend line.
(C) BT-20 cells grown as xenograft tumors in nudemice. Arrow indicates intraperit
four animals for each treatment condition.
(D–F) Time-staggered inhibition of HER2 in HER2-driven breast cancer cells (D) or
to DOX. Apoptosis measured as in Figure 1 for cells exposed to a control RNA
activation was monitored 8 hr after doxorubicin treatment (c-casp8, shown benea
the CASP8 siRNA plots. Mean values ±SD of three experiments are shown. (D) H
cancer cells treated with erlotinib. (E) NCI-H1650. (F) A-549.
(G) A model for enhanced cell death after DNA damage by chronic EGFR inhibiti
See also Figure S7.in the pretreatment condition, exactly as was seen in the setting
of TNBCs. Thus, time-staggered inhibition of EGFR in cells with
highly active EGFR signalingmay be a generalizable approach to
potentiate the effects of DNA damaging chemotherapy.
DISCUSSION
In this study, we describe a systematic time- and dose-depen-
dent approach to identifying drug combinations that are effica-
cious in killing cancer cells, depending on changes in the order
and duration of drug exposure. We found that EGFR inhibition
dramatically sensitizes a subset of TNBCs to DNA damage if
the drugs are given sequentially, but not simultaneously. Further-
more, our transcriptional, proteomic, and computational anal-
yses of signaling networks and phenotypes in drug-treated cells
revealed that the enhanced treatment efficacy results from
dynamic network rewiring of an oncogenic signature maintained
by active EGFR signaling to unmask an apoptotic process that
involves activation of caspase-8. The enhanced sensitivity to
damaging agents that we observed required sustained inhibition
of EGFR because the phenotype did not result from the rapid,
direct inhibition of the oncogene but, rather, from modulation
of an oncogene-driven transcriptional network as indicated
schematically in the model shown in Figure 7G. Furthermore,
our data suggest that it is activity of the EGFR pathway,
rather than EGFR expression per se, that determines whether
time-staggered inhibition will result in synergistic killing.
Because EGFR can be activated through a diverse set of genetic
alterations, some of which do not necessarily include EGFR itself
(Sun et al., 2011), these findings highlight the need to understand
network connectivity and dynamics (Pawson and Linding, 2008).
Conversely, these observations suggest that EGFR phosphory-
lation may constitute a useful biomarker of response to time-
staggered inhibition in at least some tumor types that are
EGFR driven, including some TNBCs and lung cancers.
A key consequence of the erlotinib-dependent dynamic
remodeling of the DDR network is activation of caspase-8
following DNA damage. The mechanism of caspase-8 activation
is unclear because it is generally thought to be specific to
receptor-mediated apoptosis triggered by ligands such as the
tumor necrosis factor (TNF) and TNF-related apoptosis-inducingptotic Response in a Subset of TNBC Cells and Other EGFR-Driven
ap for total EGFR expression, p-EGFR (Y1173), percent apoptosis, apoptosis
EGFR and p-EGFR expression are measured by western blotting of untreated
e-staggered ERL/DOX combination. Fold enrichment of cell death observed
as measured in untreated cells for the ten TNBC cell lines shown in Figure 7A.
oneal administration of indicated drugs. Mean tumor volume ±SEM shown from
EGFR in lung cancer cells (E and F) causes casp-8 activation and sensitization
(left in each panel) or siRNA targeting casp-8 (right in each panel). Caspase-8
th the control RNA plots). Validation of caspase-8 knockdown is shown below
ER2-overexpressing MDA-MB-453 cells treated with lapatinib. (E and F) Lung
on in triple-negative breast cancer cells.
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ligand (TRAIL). Possibilities include feedback activation by cas-
pase-3, possibly involving caspase-6 (Albeck et al., 2008); direct
activation of death receptors by DDRproteins (Yoon et al., 2009);
or an autocrine/paracrine mechanism involving an as-yet
unidentified death ligand. Distinguishing between these and
other possibilities will be a focus for future studies.
Combinatorial drug effects are complex, even for relatively
specific drugs like EGFR inhibitors. Our understanding of
compensation and network rewiring is currently not sufficient
to allow a priori predictions of the cellular response, particularly
in cancer cells in which signaling networks often exist in atypical
forms. Our work highlights the utility of experimental examination
of time-staggered combination treatments for their anticancer
effects, particularly when combined with an analysis of signaling
pathways and responses using mathematical modeling. These
types of approaches may facilitate the identification of effica-
cious drug combinations and new therapeutic targets and also
the design of different types of clinical trials to study the killing
of oncogene-addicted tumors through drug-induced dynamic
rewiring of signaling pathways.
EXPERIMENTAL PROCEDURES
Cellular Response Assays
Apoptosis
Following the treatment time course, cells were washed, trypsinized, fixed in
4% paraformaldehyde for 15 min at room temperature, resuspended in ice-
cold methanol, and incubated overnight at 20C. Cells were then washed
twice in PBS-Tween and stained with antibodies against cleaved caspase-3
and poly(ADP-ribose) polymerase (PARP). Secondary Alexa-conjugated anti-
bodies were used for visualization in a BD FacsCaliber flow cytometer.
Cell-Cycle Analysis
Cells were fixed in 70% ethanol overnight at20C, permeabilized with 0.25%
Triton X-100 for 20 min at 4C, blocked with 1% BSA, and incubated with anti-
phospho-histone H3. Following washing, cells were incubated with Alexa488-
conjugated secondary antibody on ice, washed, and stained with propidium
iodide (PI) prior to analysis. Data were analyzed using the Dean-Jett-Fox
algorithm.
Cell Viability/Proliferation
Cells were plated at 5,000 cells per well in 96-well plates. Metabolic viability
was determined using CellTiterGlo (Promega) according to the manufacturer’s
protocol.
Western Blotting and Antibodies
Cells were lysed in a manner that would allow samples to be used for both
western blot analysis and reverse-phase protein microarray. See Extended
Experimental Procedures for a detailed description of the cell lysis protocol
and antibodies used in this study.
Data generated by quantitative western blot were preprocessed prior to use
in computational modeling. Raw signals for each protein target of interest were
quantified and background subtracted using the Li-COR Odyssey software
and divided by b-actin signals to normalize for loading differences, and then
each normalized signal was divided by a reference sample contained on
each gel for gel-to-gel normalization.
Reverse-Phase Protein Microarray
Reverse-phase protein microarrays were printed on a fee-for-service basis
through Aushon Biosystems. Validation of antibodies, staining, and analysis
of array data was performed as described previously (Sevecka andMacBeath,
2006).
Immunofluorescence Microscopy
Cells were seeded onto coverslips and treated for the indicated times. For au-
tophagy analysis, cells were stably transfected with an mCHERRY-GFP-LC3792 Cell 149, 780–794, May 11, 2012 ª2012 Elsevier Inc.reporter construct. Cells were fixed and stained with primary antibody target-
ing either p-H2AX or 53BP1 and DAPI as above. Data reported are integrated
intensity of pH2AX or 53BP1 foci per nucleus. For autophagy measurements,
cells were scored positive if the number of GFP and mCHERRY puncta signif-
icantly increased relative to untreated cells. Approximately 100 cells were
counted in a double-blind fashion per condition. Each experiment was per-
formed in experimental triplicate.
RNA Expression Analysis by Microarray
RNA was extracted from cells using the RNAeasy Kit (QIAGEN). Affymetrix
Human U133 Plus 2.0 microarrays were hybridized, labeled, and processed
on a fee-for-service basis through the MIT BioMicro Center. Microarray data
were obtained from three independent biological replicates per time point
and analyzed using linear model for microarray (LIMMA).
Computational Modeling and Statistics
Unless otherwise noted, all statistical analyses were performed using Graph-
pad Prism, and graphs were created using Microsoft Excel, Spotfire, Matlab,
DataRail, or SIMCA-P. Analysis of flow cytometry data was performed using
FloJo. Analysis of RNA expressionmicroarray data was performed using either
GSEA or GeneGO as indicated.
Data-Driven Modeling
Data-driven modeling and the application of partial least-squares to biological
data have been described in detail previously (Janes and Yaffe, 2006). All data
were variance scaled to nondimensionalize the different measurements.
Model predictions were made via cross-validation. Model fitness was calcu-
lated using R2, Q2, and RMSE, as described previously by Gaudet et al.
(2005). VIP was calculated following Janes et al. (2008).
Xenograft Tumor Model
For in vivo tumor regression assays, 107 BT-20 cells in PBS were mixed 1:1
with matrigel on ice and injected subcutaneously into the hindflanks of nude
mice (NCR nu/nu, Taconic). Tumors were allowed to form for 7 days. Mice
were then treated intraperitoneally with doxorubicin (4mg/kg) or a combination
of doxorubicin and erlotinib (25 mg/kg), with erlotinib either given at the same
time as doxorubicin (D/E) or given 8 hr prior to doxorubicin (E/D). Tumors
were monitored for 14 days after the treatment phase, and volume was esti-
mated using the ½ L 3 W2 formula. These experiments were approved by
the Massachusetts Institute of Technology Committee on Animal Care (CAC).
ACCESSION NUMBERS
Expression data can be found in the GEO repository under the accession
number GSE30516.
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